Published in AIDS Weekly, February 24th, 2003
Tomas Hanke and colleagues at the Weatherall Institute of Molecular Medicine in Oxford, England, and the Karolinska Institutet in Stockholm, Sweden, described their "experimental subunit" vaccine, dubbed SFV.HIVA.
The in vivo immunogenicity of SFV.HIVA was comparable to that of other vaccine candidates in clinical trials, Hanke and coauthors reported.
SFV.HIVA consists of a Semliki Forest virus (SFV) vector carrying a gene coding for HIVA, a chimeric immunogen derived for HIV clade A. Mice immunized with SFV.HIVA...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2003-02-24)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.